Brief: Compugen Doses First Patient In Phase 1 Combination Study Of Com902 And Com701 In Patients With Advanced Malignancies
15/07/2021 12:20
July 15 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN DOSES FIRST PATIENT IN PHASE 1 COMBINATION STUDY
OF
COM902 AND COM701 IN PATIENTS WITH ADVANCED MALIGNANCIES
* COMPUGEN LTD - PHASE 1 COM902 MONOTHERAPY DOSE ESCALATION
STUDY
IS COMPLETE WITH INITIAL RESULTS ON TRACK FOR Q4 2021
Source text for Eikon: ID:nPn7KKRvDa
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025